Feb 19 (Reuters) - Imunon Inc IMNN.O:
IMUNON ANNOUNCES TRANSLATIONAL DATA FROM PHASE 1/2 OVATION 2 STUDY OF IMNN-001 IN ADVANCED OVARIAN CANCER
IMUNON INC - IMNN-001 SHOWS FAVORABLE SAFETY PROFILE WITH NO SERIOUS ADVERSE EVENTS
IMUNON INC - TO INITIATE PHASE 3 TRIAL OF IMNN-001 IN Q1 2025
Source text: ID:nGNXrlPq5
Further company coverage: IMNN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.